FARMINGDALE, N.Y., Sept. 14 Misonix, Inc. (Nasdaq: MSON), a developer of minimally invasive ultrasonic medical device technology, which in Europe is used for the ablation of tumors and worldwide for other acute health conditions, has announced that a patient, who wishes to remain anonymous, donated the majority of the funds necessary for Christus St. Vincent Medical Center, Santa Fe, NM, to purchase a SonicOne(R) Ultrasonic Wound Cleansing and Debridement System. The System was shipped and installed during the second half of August 2009.
Advertisement
The donation was made by a patient of Christus St. Vincent's Wound and Hyperbaric Center, where she was being treated for chronic, non-healing wounds over a lengthy period of time. During the period of clinical evaluation of the SonicOne, prior to possible purchase, the patient was treated with the SonicOne System, and, in a subsequent visit, it was noted that there was a noticeable improvement in the wound healing process. The patient wanted to move forward with additional SonicOne treatments, but was informed that the clinical evaluation was complete and a decision on purchasing the system would be made when funds became available. The patient inquired as to where a donation might be made so that the equipment could be available for her next appointment. A sizable donation was received by the St. Vincent Hospital foundation the next day, a purchase was made from the Company, and the SonicOne was delivered and installed within one week; in time for the patient's next appointment.
Advertisement
The SonicOne is an innovative, ultrasonic wound care system that offers tissue specific debridement and cleansing for effective removal of devitalized tissue and fibrin deposits while sparing viable cellular structures. The SonicOne establishes a new standard in advanced wound care and ensures progress towards patient healing.
"Misonix is always pleased to receive testimonials directly from patients who benefit from our products and technology," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We have always believed that our wound care product platform can make an important contribution to improving patient outcomes and are gratified when real life situations justify our investment in product development and clinical applications."
About Misonix:
Misonix, Inc. (Nasdaq: MSON) designs, develops, manufactures and markets therapeutic ultrasonic medical devices and laboratory equipment. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $3 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
Investor Relations Contact: Kevin McGrath / Cameron Associates, Inc. 212-245-4577 [email protected]
SOURCE Misonix, Inc.
